Efficacy of Lentinula Edodes-Derived Supplement (AHCC®) in Promoting Negativity of Persistent HPV Infection
A legfontosabb adatok
- Ki végzi
- Liaquat University of Medical & Health Sciences
- Hol
- Olaszország1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 289 fő vett részt
- Kezdés
- 2023. jan. 2.
- Befejezés
- 2024. dec. 15.
- A vizsgálat típusa
- Megfigyeléses, 3 csoport
- A vizsgált kezelések
- AHCC® (Active Hexose Correlated Compound)
- Gardasil 9®
- A regiszteradat frissítve
- 2026. január 28.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Csak nők
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 11 feltétel megnézéseKevesebb
Ki vehet részt
- Female participants aged 18 years or older
- Documented persistent high-risk HPV infection for at least 6 continuous months, confirmed by consecutive HPV-DNA tests
- Absence of high-grade cervical lesions (≤ CIN1)
- Availability of complete clinical records with evaluable HPV-DNA testing at baseline and follow-up
- Documented management with AHCC® supplementation alone, nonavalent HPV vaccination alone, or combined AHCC® supplementation and nonavalent HPV vaccination in routine clinical practice
- No prior excisional or ablative treatment of the cervix (including conization or LEEP)
Ki nem vehet részt
- History of cervical excisional or ablative treatment (including conization or LEEP)
- Presence of high-grade cervical lesions (CIN2 or worse) or invasive cervical cancer
- Conditions known to significantly alter immune function, including ongoing immunosuppressive therapy, active autoimmune disease requiring systemic treatment, or documented immunodeficiency, when such information was available in medical records
- Prior systemic antiviral or immunomodulatory therapy specifically aimed at HPV clearance during the observation period
- Incomplete clinical documentation or missing HPV follow-up data
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a retrospective, multicenter, observational study evaluating real-world HPV-DNA clearance in women with documented persistent high-risk HPV infection lasting at least six months. Clinical data were retrospectively collected from medical records of women managed in routine practice with one of three strategies: AHCC® supplementation alone, nonavalent HPV vaccination alone, or the combination of AHCC® supplementation and nonavalent HPV vaccination. The primary objective is to assess HPV-DNA clearance at 4 and 6 months following treatment initiation.
A vizsgálat 3 csoportja
- Unvaccinated with AHCC® Supplement
Women previously managed in routine clinical practice with AHCC® supplementation alone for persistent HPV infection. Participants had not received HPV vaccination prior to treatment. Clinical data were retrospectively collected from medical records to evaluate HPV-DNA clearance following this real-world management strategy.
Kezelés: AHCC® (Active Hexose Correlated Compound)
- Vaccinated with AHCC® Supplement
Women previously managed in routine clinical practice with combined AHCC® supplementation and nonavalent HPV vaccination for persistent HPV infection. Treatments were prescribed as part of standard care. Clinical data were retrospectively collected to assess HPV-DNA clearance following combined real-world exposure.
Kezelés: AHCC® (Active Hexose Correlated Compound) és Gardasil 9®
- Vaccinated Only
Women previously managed in routine clinical practice with nonavalent HPV vaccination alone for persistent HPV infection. No AHCC® supplementation was used. Clinical data were retrospectively collected to assess HPV-DNA clearance following vaccination as standard care.
Kezelés: Gardasil 9®
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Evaluation of the Efficacy and Safety of an AHCC®-Based Supplement (Lentinula Edodes) in Promoting Negativity of Persistent HPV Infection: A Retrospective Multicenter Clinical Study
- A regiszteradat frissítve
- 2026. január 28.